Online inquiry

IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15299MR)

This product GTTS-WQ15299MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Allergic asthma, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15299MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11930MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ1502MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ650MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ115MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ12352MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ7271MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ8018MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ7501MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW